Multiple sclerosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD20 17
• CD19 10
• PPAR 0
• NLRP3 0
• STAT3 0
• BCMA 13
• BTK 1
• IL-17 0
• NRF2 0
• TNF 0
• AQP4 0
• GLP-1 2
• AMPK 0
• BDNF 1
• AKT 0
• IL-6 0
• mTOR 0
• CD40 0
• JAK 0
• PI3K 0
• STING 0
• TREM2 0
• PD-1 0
• IL-1 0
• IL-4 0
• SIRT1 0
• TLR4 0
• AXL 0
• CGRP 0
• CSF1R 0
• HIF-1 0
• IL-23 0
• VEGF 1
• COX-2 0
• CTLA-4 0
• CXCR4 0
• ERK 0
• HMGB1 0
• HSP90 0
• PD-L1 0
• TYK2 1
• APOE 0
• CCR5 0
• CTNNB1 0
• EGFR 0
• FOXP3 0
• GPX4 0
• IDO1 0
• JNK 0
• PARP 0
• PTEN 0
• TP53 1
• ACE2 0
• APP 0
• BCL-2 0
• BRD4 0
• C9orf72 0
• CDK4/6 0
• G6PD 0
• HDAC 0

12 of 12+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Artificial intelligence and WeArables for the undeRstanding and Evaluation of Multiple Sclerosis (AWARE-MS)

  Scuola Superiore di Studi Universitari e di Perfezionamento S Anna· Pisa, Italy· EU contribution €420,751· until Mar 2030· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Astrocytic exhaustion underlies chronic progression in autoimmune inflammation of the central nervous system (AXhaustMS)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,638,843· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular regulation of the axon–myelin interface in development and repair (MInDRe)

  The University of Edinburgh· Edinburgh, United Kingdom· EU contribution €260,348· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Harnessing engineered lipid nanoparticles to tame autoimmune neuroinflammation by inducing regulatory T cells through CNS myeloid reprogramming (LipoTAME)

  Vrije Universiteit Brussel· Bruxelles / Brussel, Belgium· EU contribution €200,400· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting myeloid cell states, actions and interactions in neuroinflammation (TACO)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €2,471,050· until Dec 2031

5 of 46 running projects, newest first. Listed amounts together: €130.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Sanofi· Source

• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Sanofi· Source

• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Sanofi· Source

• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Sanofi· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 39
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 29
• Magnetic Resonance Imaging 570
• Machine Learning 43
• Deep Learning 33
• Cohort Studies 183
• Genome-Wide Association Study 84

• Central Nervous System Inflammatory and Infectious Disease.

  Neuroimaging Clin N Am, Sept 2026

• Evaluating the Clinical Utility of TSPO-PET in MS and the Influence of Methodological Heterogeneity: A Systematic Review and Meta-Analysis.

  Neurol Neuroimmunol Neuroinflamm, Sept 2026

• Complementary PET and MRI of myeloperoxidase activity as a noninvasive surrogate for tissue acrolein in experimental neuroinflammation.

  Neuroimage, Sept 2026

• Smoldering neuroinflammation in progressive multiple sclerosis: mechanisms, imaging biomarkers, and therapeutic opportunities.

  Front Immunol, Sept 2026

• PARP inhibition attenuates neuroinflammation and demyelination in a rat model of multiple sclerosis: A longitudinal [11C]PBR28 TSPO PET imaging study.

  Neurotherapeutics, Aug 2026

• Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression.

  Brain, Jun 2026

• Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis.

  J Neurol, Jun 2026

• TSPO-PET-measurable neuroinflammation associates with information processing speed decline in multiple sclerosis.

  Mult Scler, May 2026

• The design, synthesis and evaluation of the first carbon-11 positron emission tomography radiotracer for ASK1 imaging.

  Bioorg Chem, May 2026

• Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.

  J Neurol, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.